Fida Biosystems develops analytical instruments based on its proprietary Flow Induced Dispersion Analysis (FIDA) technology, enabling fast and accurate measurement of biomolecules and nanoparticles directly in complex biological samples. The platform helps pharmaceutical and biotech researchers better understand molecular behaviour, ultimately accelerating the creation of new medicines. Commercial traction is growing, with more than 100 instruments sold to industry and leading research institutions. Over the past year the company has doubled its revenue, signalling strong product-market fit. Management plans to leverage this momentum to scale sales and prepare for a forthcoming Series B growth round. The recent capital infusion reinforces the firm’s financial position and supports continued product development and commercial expansion.

Total raised

$6M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2025